ISIN | CH0113817065 |
---|---|
Valor Number | 11381706 |
Bloomberg Global ID | BBG0017T9CP3 |
Fund Name | Bellevue Biotech AA CHF |
Fund Provider |
Bellevue Asset Management AG
Zürich, Switzerland Phone: +41 44 267 67 00 E-Mail: info@bellevue.ch Web: www.bellevue.ch |
Fund Provider | Bellevue Asset Management AG |
Representative in Switzerland | |
Distributor(s) |
Zürcher Kantonalbank Zürich Phone: +41 44 293 93 93 |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Distribution |
Home Country | Switzerland |
Issuing Condition | Special conditions apply to the issue of units |
Redemption Condition | Special conditions apply to the redemption of units |
Investment Strategy *** | N/A |
Peculiarities |
Current Price * | 3,370.12 CHF | 17.09.2024 |
---|---|---|
Previous Price * | 3,372.94 CHF | 16.09.2024 |
52 Week High * | 3,593.23 CHF | 16.07.2024 |
52 Week Low * | 2,786.89 CHF | 27.10.2023 |
NAV * | 3,370.12 CHF | 17.09.2024 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 37,887,938 | |
Unit/Share Assets *** | 12,902,868 | |
Trading Information SIX |
YTD Performance | +8.98% |
29.12.2023 - 17.09.2024
29.12.2023 17.09.2024 |
---|---|---|
1 month | -0.93% |
19.08.2024 - 17.09.2024
19.08.2024 17.09.2024 |
3 months | +3.90% |
17.06.2024 - 17.09.2024
17.06.2024 17.09.2024 |
6 months | +4.74% |
18.03.2024 - 17.09.2024
18.03.2024 17.09.2024 |
1 year | +9.54% |
18.09.2023 - 17.09.2024
18.09.2023 17.09.2024 |
2 years | +1.04% |
19.09.2022 - 17.09.2024
19.09.2022 17.09.2024 |
3 years | -20.70% |
17.09.2021 - 17.09.2024
17.09.2021 17.09.2024 |
5 years | +17.23% |
17.09.2019 - 17.09.2024
17.09.2019 17.09.2024 |
Equity Participation Rate in % | 82.38 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | 0.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | 11.6387 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date | 17.09.2024 |
Regeneron Pharmaceuticals Inc | 8.07% | |
---|---|---|
Vertex Pharmaceuticals Inc | 7.92% | |
Amgen Inc | 7.90% | |
Gilead Sciences Inc | 5.38% | |
AstraZeneca PLC ADR | 4.00% | |
Moderna Inc | 3.33% | |
Alnylam Pharmaceuticals Inc | 3.08% | |
Biogen Inc | 2.62% | |
argenx SE ADR | 2.52% | |
Neurocrine Biosciences Inc | 2.48% | |
Last data update | 31.07.2024 |
TER | 1.81% |
---|---|
TER date | 29.09.2023 |
Performance Fee *** | 10.00% |
PTR | |
Max. Management Fee *** | 2.00% |
Ongoing Charges *** | 1.81% |
SRRI ***
|
|
SRRI date *** | 31.08.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |